[1] Khemlina G,Ikeda S,Kurzrock R.The biology of hepatocellular carcinoma:implications for genomic and immune therapies. Mol Cancer,2017,16(1):149. [2] Yegin EG,Oymaci E,Karatay E,et al.Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary Pancreat Dis Int,2016,15(3):234-256. [3] Bruxi J,Reig M,Sherman M.Evidence-based diagnosis,staging,and treatment of patients with hepatocellular carcinoma. Gastroenterology,2016,150(4):835-853. [4] Lan QY,Liao GC,Zhou RF,et al.Dietary patterns and primary liver cancer in Chinese adults:a case-control study. Oncotarget,2018,9(45):27872-27881. [5] Seguin P,Locher RC,Bound Jema K,et al.Effect of a perioperative nutritional supplementation with oral impact in patients undergoing hepatic surgery for liver cancer:A prospective,placebo-controlled,randomized,double-blind study. Nutr Cancer,2016,68(3):464-472. [6] Song W,Wang K,Zhang RJ,et al.The enhanced recovery after surgery(ERAS) program in liver surgery:a Meta-analysis of randomized controlled trials. Springerplus,2016,5(1):207-217. [7] Rouxel P,Beloeil H. Enhanced recovery after hepatectomy:A systematic review. Anaesth Crit Care Pain Med,2018:S2352-5568(18)30043-30052. [8] Kawada J,Nishino M,Hata T,et al.Analysis of patients who received enteral nutrition in the course of chemotherapy. Gan To Kagaku Ryoho,2017,44(10):900-902. [9] 韩玉龙,苗健,尹家俊. 不同肝血流阻断方案对手术切除原发性大肝癌患者治疗效果比较. 实用肝脏病杂志,2018,21(1):104-107. [10] 汪佩文,董育玮,李郑红,等. 94例不明原因肝功能异常患者临床与肝组织病理学分析. 实用肝脏病杂志,2018,21(2):225-228. [11] Williams JM,Greenslade JH,Mckenzie JV,et al.Systemic inflammatory response syndrome,quick sequential organ function assessment,and organ dysfunction:Insights from a prospective database of ED patients with infection. Chest,2017,151(3):586-596. [12] Zhao J,Kmc VM,Gómez-Ramírez J,et al.Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg,2017,104(8):990-1002. [13] Komardina E,Yaroustovsky M,Abramyan M,et al.Prometheus therapy for the treatment of acute liver failure in patients after cardiac surgery. Kardiochir Torakochirurgia Pol,2017,14(4):230-235. [14] Sato K,Kuroda S,Kobayashi T,et al. A case report on the successful perioperative management of hepatectomy for hepatocellular carcinoma in a patient with von Willebrand disease. Int J Surg Case Rep,2018,[ahead of print]. [15] Mehta NM,Coss-BuJ A,Liam McKeever MS RDN,et al. Guidelines for the provision and assessment of nutrition support therapy in the pediatric critically ill patient. Pediatr Crit Care Med,2017,41(5):706. [16] 雍伟. 早期肠内免疫微生态营养对原发性肝癌患者术后临床疗效的影响. 实用肝脏病杂志,2017,20(3):328-332. [17] Mcclave SA,Chang WK,Dhaliwal R,et al.Nutrition support in acute pancreatitis:A systematic review of the literature. JPEN J Parenter Enteral Nutr,2006,30(2):143-156. [18] Chiba H, Endo K,Izumiyama Y,et al.Usefulness of a peripherally inserted central catheter for total parenteral nutrition in patients with inflammatory bowel disease. Nihon Shokakibyo Gakkai Zasshi,2017,114(9):1639. [19] Yao H,Bian X,Mao L,et al.Preoperative enteral nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma:A strengthening the reporting of observational studies in epidemiology article. Medicine,2015,94(46):e2006. [20] Qiao Y,Xu M,Tao J,et al.Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice BMC Cancer,2018,18(1):1093. [21] Van Tong H,Van Ba N,Hoan NX,et al.Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases. BMC Infect Dis,2018,18(1):553. [22] Yao Z,Dong Y,Wu G,et al.Preoperative diagnosis and prediction of hepatocellular carcinoma:Radiomics analysis based on multi- modal ultrasound images. BMC Cancer,2018,18(1):1089. [23] Wu H,Zhao W,Zhang J,et al.Clinical characteristics of hepatic Arterioportal shunts associated with hepatocellular carcinoma. BMC Gastroenterol,2018,18(1):174. |